#154622

ZR-75-1 BCAR3 [B3-10] cell line

Cat. #154622

ZR-75-1 BCAR3 [B3-10] cell line

Cat. #: 154622

Sub-type: Continuous

Unit size: 1x10^6 cells / vial

Availability: 3-4 weeks

Organism: Human

Tissue: Breast

Disease: Cancer

Model: Cancer Model

£575.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Lambert Dorssers

Institute: Erasmus University Medical Center (Erasmus MC)

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: ZR-75-1 BCAR3 [B3-10] cell line
  • Alternate name: Breast Cancer Anti-Estrogen Resistance 3; SH2 Domain-Containing Protein 3B; NSP2
  • Cancer: Gynaecologic cancer
  • Cancers detailed: Mammary ductal carcinoma
  • Research fields: Cancer;Drug development
  • Tool sub type: Continuous
  • Parental cell: ZR-75-1
  • Organism: Human
  • Tissue: Breast
  • Disease: Cancer
  • Model: Cancer Model
  • Description: Breast cancer is widely and effectively treated with endocrine treatment. However, in many cases the tumours will eventually progress into an estrogen-independent and therapy-resistant phenotype.Seven genes including AKT1, AKT2, BCAR1, BCAR2, BCAR3, EGFR2 and GRB7 have been shown to directly underlie estrogen independence in human breast cancer cells. This cell line is part of a panel of 16 cell lines (Cat No 154621-154635, 154642) which have been transfected with these genes, plus the parental (Cat No 154547).This cell line is a powerful tool for studying the molecular and cellular mechanisms of breast tumour progression, therapy resistance and to test the effectiveness of novel drugs to combat different modes of anti-estrogen insensitivity
  • Production details: Full length BCAR3 cDNA was introduced in the estrogen-dependent ZR-75-1 cell line by transfection with lipofectamine
  • Biosafety level: 1

Target Details

  • Target: BCAR3

Applications

  • Application notes: The cell line is resistant to Geneticin, which may be included in the culture medium to ensure that the expression vector is retained by the cells. As a consequence of the presence of a BCAR genes, these cells can also proliferate in the absence of estrogen or even in the presence of anti-estrogens.

Handling

  • Format: Frozen
  • Growth medium: RPMI 1640 medium supplemented with 10% heat-inactivated bovine serum (RBCS) and 1 nM 17?-estradiol
  • Unit size: 1x10^6 cells / vial
  • Shipping conditions: Dry ice
  • Storage conditions: Liquid Nitrogen
  • Mycoplasma free: Yes

References

  • van Agthoven et al. 1998. EMBO J. 17(10):2799-808. PMID: 9582273.